ClinicalTrials.gg
RecruitingNCT04414865Updated Jun 4, 2020

VitaFlow™ Transcatheter Aortic Valve System Post-market Study-The LAUNCH Study

An observational study in Aortic Valve Stenosis, sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd. (part of MicroPort Scientific Corporation) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2021, 4 years 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2020; still recruiting 6 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.

Planned enrollment
17th of 22
100 · median 490
Started
2020
with 5 others
Observational
22 of 69
16 open now
Primary completion
2021-12
later than 4 of 50 live
Registered
14th of 69
by date
Lead sponsor
6 of 69
Shanghai MicroPort CardioFlow Medtech Co., Ltd.

Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 17th largest by planned enrollment of the 22 observational ones that give a count, is one of 6 that started in 2020, is one of 22 observational ones, reaches primary completion later than 4 of the 50 other live ones, and was the 14th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Aortic Valve Stenosis with a site in China, or all of them as a file.
02

Study summary

The study objective is to evaluate safety and effectiveness/performance of the Microport™ CardioFlow VitaFlow™ Transcatheter Aortic Valve System for the treatment of severe aortic stenosis in the real world settings.

Read the detailed description

This is a prospective, single-arm, multi-center, observational, post-market registry study. The purpose is to evaluate the safety, performance, and effectiveness of the VitaFlow™ Transcatheter Aortic Valve System in the real world settings.Patients will be seen at pre and post procedure, discharge, 30 days, 1 year and annually up to 5 years.

03

Conditions studied

  • Aortic Valve Stenosis
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes symptomatic patients (≥70 years old ) with calcified, severe, degenerative, native aortic valve stenosis who are not suitable for the surgical aortic valve replacement as assessed by the heart team

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age≥70 years;
  • Symptomatic , calcified, severe, degenerative, native aortic valve stenosis : peak velocity ≥4.0m/s, or mean transvalvular gradient ≥40mmHg(1 mmHg=0.133kPa), or aortic valve area\<0.8cm² (or EOA index\<0.5cm²/m²);
  • The patients considered to be not suitable for surgical aortic valve replacement (SAVR);
  • The patient has been informed of the nature of the study, is willing to enroll in the study by signing a patient and agreeing to the scheduled follow up requirement.

Exclusion criteria

Exclusion Criteria:

  • Aortic root anatomy not suitable for the implantation of the transcatheter aortic valve;
  • Vascular diseases or anatomical condition preventing the device access;
  • Previous implantation of mechanical or bioprosthesis valve in the aortic position;
  • Known or to all anticoagulation/antiplatelet regimens, to nitinol, contrast media or other relevant elements;
  • Ongoing sepsis, including active endocarditis;
  • Estimated \< 12 months;
  • Participating in another trial and the primary endpoint is not achieved.
  • Inability to comply with the clinical investigation follow-up or other requirements.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • single arm, treatment group

    Subjects in the treatment group will be implanted with the VitaFlow™ Transcatheter Aortic Valve System

    Device: VitaFlow™ Transcatheter Aortic Valve System

Interventions

  • DeviceVitaFlow™ Transcatheter Aortic Valve System

    VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set

06

What researchers measure

Primary outcomes

  1. Rate of all-cause mortality at 12 months post implantation

    Rate of all-cause mortality including cardiovascular and non-cardiovascular death

    Time frame: 12 months post implantation

Secondary outcomes

  1. Valve function-mean transvalvular gradient

    Mean transvalvular gradient measured by transthoracic echocardiography (TTE)(in mmHg)

    Time frame: at discharge, 30 days, 1 year and annually up to 5 years post implantation

  2. Valve function-effective orifice area

    Effective orifice area measured by transthoracic echocardiography (TTE)(in cm\^2)

    Time frame: at discharge, 30 days, 1 year and annually up to 5 years post implantation

  3. Valve function-degree of prosthetic valve regurgitation

    Degree of prosthetic valve regurgitation, including paravalvular leak and intravalvular regurgitation measured by transthoracic echocardiography (TTE)

    Time frame: at discharge, 30 days, 1 year and annually up to 5 years post implantation

  4. Rate of safety events according to VARC2

    Rate of safety events according to VARC2 including all-cause mortality, myocardial infarction, stroke, bleeding, acute kidney injury, vascular complications, new permanent pacemaker implantation

    Time frame: at immediate, 30 days, 1 year and annually up to 5 years post implantation

  5. Rate of other TAVI-related complications

    Rate of other TAVI-related complications including conversion to open surgery, unplanned use of cardiopulmonary bypass, coronary obstruction, ventricular septal perforation, mitral valve apparatus damage or dysfunction, cardiac tamponade, endocarditis, valve thrombosis, valve mal-positioning, TAV-in-TAV, valve related dysfunction requiring repeat procedure (TAVI,SAVR,BAV)

    Time frame: at immediate, 30 days, 1 year and annually up to 5 years post implantation

  6. Rate of device success

    Rate of device success, assessed by the access, delivery, deployment and implantation of the device and the prosthetic valve function

    Time frame: at immediate post implantation

  7. Rate of balloon pre-dilatation success

    Rate of balloon pre-dilatation success, assessed by the access, delivery, pre-dilatation and retrieval of the balloon catheter

    Time frame: at immediate post implantation

  8. Rate of balloon post-dilatation success

    Rate of balloon pre-dilatation success, assessed by the access, delivery, post-dilatation and retrieval of the balloon catheter

    Time frame: at immediate post implantation

  9. Rate of procedure success

    Rate of procedure success, assessed by the device success and peri-procedural complications

    Time frame: at immediate post implantation

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2020 (actual). Primary completion is estimated for Dec 2021, 19 months after the start.

Of 37 industry-sponsored observational studies under Aortic Valve Stenosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 19 months is below that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2020
First posted
Jun 4, 2020
StartActual
Apr 26, 2020
Primary completionEst.
Dec 1, 2021
CompletionEst.
Dec 30, 2027
Last update
Jun 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04414865
Responsible party
Sponsor
First posted
Jun 4, 2020
Start date
Apr 26, 2020
Primary completion
Dec 1, 2021 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Jun 4, 2020

Study contacts

Zhujun Cai, PhD
Contact
zjcai@micoport.com
(86)(21)38954600
Jie Bi
Contact
jbi@micoport.com
(86)(21)38954600

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion